Amlintide

Base Information

• Chemical Name: Amlintide
• CAS No.: 122384-88-7
• Deprecated CAS: 126698-61-1
• Molecular Formula: C165H261N51O55S2
• Molecular Weight: 3903.31
• Hs Code.: 2937190000
• NCI Thesaurus Code: C169781
• Mol file: 122384-88-7.mol

Synonyms:amlintide;amylin;Amylin, Pancreatic;Amyloid Polypeptide, Insulinoma;Amyloid Polypeptide, Islet;IAPP precursor;IAPP protein;insulinoma amyloid polypeptide;insulinoma amyloid polypeptide precursor;islet amyloid polypeptide;islet amyloid polypeptide precursor;pancreatic amylin;Polypeptide, Insulinoma Amyloid;Polypeptide, Islet Amyloid

Chemical Property of Amlintide

Chemical Property:

• PSA: 1808.07000
• LogP: -5.38340
• Storage Temp.: −20°C
• Water Solubility.: Soluble to 5 mg/ml in water and in 5% acetic acid.
• XLogP3: -18.7
• Hydrogen Bond Donor Count: 61
• Hydrogen Bond Acceptor Count: 61
• Rotatable Bond Count: 115
• Exact Mass: 3901.8669088
• Heavy Atom Count: 273
• Complexity: 9390

Purity/Quality:

98%,99%, ^*data from raw suppliers

IAPP ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)N)NC(=O)C(C)NC(=O)CNC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC3=CN=CN3)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C5CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N5)C(C)O)C)C(C)O)CC(=O)N)NC(=O)C(CCCCN)N
• Isomeric SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]5CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N5)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N
• Biological functions: AMY reduces blood glucose levels. AMY is reported to suppress glucagon release from pancreatic β cells and is therefore considered to play a role in glucose homeostasis. There have been contradictory reports regarding the in vitro effects of AMY on insulin secretion. AMY may have dual effects on insulin release, which stimulates basal insulin secretion and suppresses it when insulin secretion is augmented. A number of studies have been carried out on the autocrine/paracrine functions of pancreatic AMY, but the mechanisms are still largely unknown. AMY is believed to inhibit food intake and gastric emptying in relation to satiety center stimulation. AMY has also been reported to inhibit insulin-stimulated glucose uptake and the synthesis of glycogen in isolated rat skeletal muscle.
• Description: Amylin is a 37-peptide that is structurally similar to CT. Amylin works together with insulin to regulate glucose concentrations after a meal. When in solution, amylin is viscous, unstable, and tends to aggregate; therefore it cannot be used parenterally and is not commercially available.
• Uses: Amylin functions as part of the?endocrine?pancreas?and contributes to?glycemic control. It functions as a synergistic partner to insulin. The overall effect is to slow the rate of appearance (Ra) of glucose in the blood after eating. Antidiabetic.
• Clinical Use: Amylin normally is cosecreted with insulin from secretory granules in pancreatic β cells in response to meals and works with insulin to provide postprandial glucose control. Native amylin is a single-chain peptide of 37 amino acids. Observed deficiencies of amylin in both type 1 and type 2 patients treated with insulin have led to research and drug development related to amylin. Pramlintide, whose sequence is based on rat AMY to avoid amyloid formation, is used for the treatment of type 1 and type 2 diabetes to reduce blood glucose levels.